Early Automation Integration Reshapes How Drugs Move From Lab To Production

Automation has typically entered pharmaceutical development late, sometimes just before process performance qualification, leaving teams to build control recipes, integrate equipment, and write procedures under pressure. Caleb Eastman, Field CTO for the Americas at Siemens, argues that the fix is structural rather than incremental. He looks at how a data orchestration layer and vendor-agnostic control standards change what can be done in Phases 1 and 2, how the same control logic can span bench, pilot, and production volumes, and what earlier integration means for audit-ready parameter lineage and continuous process verification. For anyone weighing how to shorten technology transfer without adding scale-up risk, Eastman's perspective is worth a close look.

See how he connects data and automation strategy.